Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: A randomized double-blind clinical trial (NCT00461916)

Human Reproduction

Volumn 22, Issue 9, 2007, Pages 2449-2454

  Safdarian, Leili ^a   Mohammadi, Farnoosh Soltani ^a   Alleyassin, Ashraf ^a   Aghahosseini, Marzieh ^a   Meysamie, Alipasha ^b   Rahimi, Eiman ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Controlled ovarian stimulation; Daily buserelin; Depot triptorelin; ICSI; Long protocol

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; DIPHERELIN; ETHINYLESTRADIOL; HUMAN MENOPAUSAL GONADOTROPIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; EMBRYO TRANSFER; FEMALE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY;

EID: 34548107819     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem223     Document Type: Article

References (34)

1. Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 2004;81:1207-1220.
2. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotruphin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2005;CD002808.
3. Baka S, Makrakis E. Tzanakaki D, Konidaris S, Hassiakos D, Moustakarias T, Creatsas G. Poor responders in IVF: Cancellation of a first cycle is not predictive of a subsequent failure. Ann N Y Acad Sci 2006; 1092:418-425.
4. Balasch J, Gomez F, Casamitjana R, Carmona F, Rivera F, Vanrell JA. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod 1992;7:1230-1234.
5. Biljan MM, Mahutte NG, Dean N, Hemmings R. Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues, and on subsequent implantation and pregnancy rates. Fertil Steril 1998;70:1063-1069.
6. Burney RO, Schust DJ, Yao MWM. Infertility. In: Berek JS (ed). Berek and Novak's Gynecology. Los Angeles: Lippincott Williams & Wilkins, 2006, 1186-1275.
7. Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: A randomized study. Hum Reprod 2004;19:2200-2205.
8. Dal Prato L, Borini A, Trevisi MR, Bonu MA, Sereni E, Flamigni C. Fffect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: A randomized study. Hum Reprod 2001;16 1409-1414.
9. Dor J, Bider D, Shulman A, Levron J, Shine S, Mashiach S et al. Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro - results of a prospective, randomized in-vitro fertilization study. Hum Reprod 2000;15: 1225-1230.
10. Elgendy M, Afnan M, Holder R, Lashen H, Afifi Y, Lenton W, Sharif K. Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: Effect on ovarian response and in-vitro fertilization outcome. Hum Reprod 1998;13:2382-2385.
11. Fabregues F, Penarrubia J, Creus M, Casamitjana R, Vanrell JA, Balasch J. Effect of halving the daily dose of triptorelin at the start of ovarian stimulation on hormone serum levels and the outcome of in vitro fertilization. Fertil Steril 2005;83:785-788.
12. Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: A randomized controlled trial. Hum Reprod 2006;21 2628-2632.
13. Gerrero H, Stein P, Asch R, de Fried E, Tesone M. Effect of a gonodotropin-releasing hormone agonist on luteinizing homone receptors and steroidogenesis in ovarian cells. Fertil Steril 1993;59 803-808.
14. Gonen Y, Jacobson W. Casper RF, Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril 1990;53:282-287.
15. Hamberger L, Lundin Y, Sjogren A. Indications for intracytoplasmic sperm injection. Hum Reprod 1998;13(Supp 1):128-133.
16. Hsieh Y, Tsai H, Chang C, Chang C, Lo H. Comparison of a single half-dose, longacting form of gonadotropin-releasing hormone analog (GnRH-a) and a short acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program, Fertil Steril 2000;73: 817-820.
17. Hugues J, Cedrin-Durnerin I. Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update 1998;4:83-101.
18. Janssens RM, Lambaik CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, Schoemaker J. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000; 15:2333-2340.
19. Kilani Z. Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, Filicori M. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: Ovarian response and clinical outcomes. Hum Reprod 2003;18: 1194-1199.
20. Lenton E, Mohamed K. Optimizing assisted reproduction: Impact of low-dose gonadotropin-releasing hormone agonist on in vitro fertilization outcome. Fertil Steril 2005;84:1783-1785.
21. Murad NM. Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring. Int J Gynaecol Obstet 1998;63 271-276.
22. Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC. Pituitary down-regulation prior to in-vitro fertilization and embryo tranfer: A comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact. Hum Reprod 1995;10:1042-1044.
23. Penarrubia J, Fabregues F, Creus M, Manau D, Casamitjana R, Guimera M, Carmona F, Vanrell JA, Balasch J. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Hum Reprod 2003;18:2689-2697.
24. Peng C, Fan NC, Ligier M, Vaananen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GNRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 1994; 135:1740-1746.
25. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004;4:26.
26. Sandow J, Donnez J. Clinical pharmacokinetics of LHRH analogues. In: Brosens I, Jacobs HS, Runnebaum B (ed). LHRH Analogues in Gynaecology Carnforth, Lancashire: Parthenon Publishing, Casterton Hall, 1990, 17-31.
27. Simon A, Benshushan A, Shushan A, Zajicek G, Dorembus D, Lewin A. Laufer N. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization. Hum Reprod 1994;9:1813-1817.
28. Takeuchi S. Minoura H, Shibahara T, Tsuiki Y, Noritaka. F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2001;76:532-537.
29. Tan B, Vandekerckhove P, Keay S. Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI. Cochrane Database Syst Rev 2006;4.
30. Tsai HD, Chen CM, Lo HY, Chang CC. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod 1995;10 2909-2912.
31. Tsai NM, Hsieh RH, Au HK, Shieh MJ, Huang SY, Tzeng CR. Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci 2005;1042:531-537.
32. Turhan NO. Poor response-the devil is in the definition. Fertil Steril 2006;85:e1.
33. Veeck LL. An Atlas of Human Gametes and Conceptuses: An Illustrated Reference for Assisted Reproductive Technology. New York CRC Press Parthenon Publishiing, 1999.
34. Yim SF, Lok IH, Cheung LP, Briton-Jones CM, Chiu TT, Haines CJ. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod 2001;16:492-494.